351 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (182)
- Autoimmune Disorders (3)
- Blood Disorders (8)
- Cancer
(111)
- Bladder Cancer (1)
- Brain Cancer (2)
- Breast Cancer (2)
- (-) Gastrointestinal (3)
- Gynecologic Cancer (3)
- Head and Neck Cancer (2)
- Kidney Cancer (3)
- Leukemia (9)
- Liver Cancer (1)
- Lung Cancer (14)
- Lymphoma (8)
- Multiple Myeloma (6)
- Pancreatic Cancer (1)
- Prostate Cancer (9)
- Sarcoma (4)
- Skin Cancer (5)
- Solid Tumors (7)
- Diabetes (1)
- Healthy Volunteers (3)
- (-) Heart Disease (2)
- Infectious Disease (3)
- Neurological Disorders (16)
- Nutrition (1)
- Obstetrics & Gynecology (1)
- Pediatrics (15)
- Psychiatric Disorders (1)
- Transplant (16)
- Urology (1)
Displaying 1 - 5 of 5
Condition: Valve Disease / Tricuspid Valve Disease
Investigator: Susheel Kodali, MD
Status: Currently Recruiting
The goal of this early feasibility study is to gain initial insight into the basic safety and performance of transluminal (through the blood vessels) implantation of the PASCAL System's implant (composed of man-made materials). We are trying to evaluate the safety and performance of the PASCAL System…
Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
The purpose of this study is safety, tolerability and efficacy of a combined treatment of LBL-007 and tislelizumab in combination with bevacizumab and capecitabine. LBL-007 and tislelizumab has not yet been approved by the Food and Drug Administration (FDA). Bevacizumab and capecitabine are approved for use in colorectal cancer, but their use in combination…
Condition: Heart Disease
Investigator: Maryjane Farr, MD
Status: Closed
In this study, patients with heart failure, will undergo a cardiac catheterization procedure which either includes injections of stem cells from healthy young adults into the heart or a sham (mock) procedure that does not include injection of the stem…
Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
The purpose of this study is to determine if the study drugs, encorafenib, and cetuximab, taken in combination with pembrolizumab would improve compared to the outcome of pembrolizumab alone in study patients. Encorafenib and cetuximab target cancerous BRAF proteins and potentially slow down the growth of cancer cells.…
Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
This study evaluates whether the addition of immune therapy to usual FOLFOX chemotherapy in patients with deficient DNA mismatch repair stage III colon cancer can improve your outcome compared to FOLFOX alone. The immune therapy drug, atezolizumab, may allow your body's immune system to more effectively kill cancer…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE